StockNews.AI
CAPR
StockNews.AI
36 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

1. Pomerantz LLP is investigating securities fraud claims against Capricor. 2. Capricor's stock fell significantly after FDA advisory committee cancellation. 3. Investors are advised to reach out regarding potential class action participation. 4. Capricor’s BLA for deramiocel faced setbacks and uncertainty over drug efficacy. 5. Stock price has seen volatile movements linked to FDA interactions.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Recent investigations and FDA setbacks have significantly undermined investor confidence, similar to past incidents in biopharmaceutical firms where major clinical trial failures have led to drastic stock declines.

How important is it?

The severity of the investigation and substantial stock price drops following FDA news makes this situation critical for CAPR's valuation and potential recovery.

Why Short Term?

The ongoing investigation and negative FDA news are likely to affect CAPR's performance in the immediate future, reminding investors of past examples where similar situations led to rapid stock price reductions.

Related Companies

SRPTPTCTNVS
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 5, 2025, Capricor issued a press release announcing that after “the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had “confirmed its intent to hold an advisory committee meeting” in connection with the BLA.  On this news, Capricor’s stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025.  Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug’s efficacy and safety.  On this news, Capricor’s stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News